Welcome!
CGS-CIMB Research
Broker's Calls
SGX FY2022 results divide analysts, DBS issues lowest TP of $10.20
“We believe there are no immediate catalysts for the stock, with the mixed performance of FY2022 equities and derivative volumes.”
August 22, 2022
Broker's Calls
CGS-CIMB downgrades Q&M, slashes TP to 44 cents; PhillipCapital lowers TP to 60 cents on near-term challenges
Despite the lower target price, Tay and Tan believe the market has already priced in the group’s near-term challenges.
August 19, 2022
Broker's Calls
Yangzijiang Financial on track to hit AUM target, CGS-CIMB keeps 'add'
The analysts include faster-than-expected AUM growth as one of the key catalysts.
August 19, 2022
Broker's Calls
Likely a decent start to FY2023 for Singtel: CGS-CIMB
Singtel is expected to see a q-o-q improvement in its upcoming 1Q results.
August 19, 2022
Broker's Calls
Broker's Digest: Sasseur REIT, HRnetGroup, Grand Venture Technology, Food Empire
See what the analysts have to say this week.
August 18, 2022
Broker's Calls
CGS-CIMB downgrades Sea after 2QFY22 results, Maybank maintains ‘buy’ call
CGS-CIMB calls "sell", but Maybank calls "buy" on Sea.
August 18, 2022
Broker's Calls
Jiutian's 'strong' 2QFY2022 results earn 87.5% upside TP from CGS-CIMB
2QFY2022 net profit of RMB184 million ($37.49 million) was up 163% y-o-y.
August 18, 2022
Broker's Calls
'Add' Hyphens Pharma as it moves on to its next phase of growth
CGS-CIMB Research is betting on Hyphens Pharma's next phase of growth.
August 18, 2022
Broker's Calls
Analysts maintain 'buy' on UMS, seeing strong order forecasts
DBS raises their target price to $1.83, but CGS-CIMB leaves theirs unchanged.
August 17, 2022
Broker's Calls
Most analysts call ‘buy’ on ST Engineering, but Citi calls ‘sell’
Find out why Citi handed a "sell" rating to STE when others were calling "buy"
August 16, 2022